A judge ruled that two patents related to Vanda Pharmaceuticals’ schizophrenia drug Fanapt were valid and one of them was infringed upon by Roxane Laboratories.

U.S. District Judge Gregory Sleet issued a permanent injunction blocking Roxane from infringing on the patents before their November 2027 expiration date.

According to court documents, Roxane filed an ANDA for an antipsychotic drug and included a certification that in its opinion the Vanda patents claims are invalid and/or that certain claims will not be infringed.

Roxane did not, however, allege that the patent claims covering iloperidone, the active ingredient in Fanapt, will not be infringed.